恩夫韦肽
病毒进入
肽
蛋白酶
进入抑制剂
病毒学
逆转录酶
人类免疫缺陷病毒(HIV)
药物开发
病毒复制
生物
药理学
第41页
药品
表位
病毒
酶
免疫学
抗体
核糖核酸
生物化学
基因
作者
Jing Pu,Qian Wang,Shibo Jiang
出处
期刊:Springer eBooks
[Springer Nature]
日期:2022-01-01
卷期号:: 15-26
标识
DOI:10.1007/978-981-16-8702-0_2
摘要
The development of peptide-based HIV entry inhibitors has made an important contribution to the stock of anti-HIV drugs. In particular, the peptide-based anti-HIV drugs enfuvirtide and albuvirtide were approved for clinical use by the U.S. FDA and CFDA in 2003 and 2018, respectively. Peptide-based HIV entry inhibitors exert antiviral activity by targeting the early stage of viral infection, i.e., binding of a viral surface protein to the receptor(s) on the host cell and the subsequent fusion between the viral and host cell membranes. Therefore, they are particularly useful for HIV-infected patients who have failed to respond to the highly active antiretroviral drugs (ARD) targeting the late stage of HIV replication, such as reverse transcriptase inhibitors and protease inhibitors. In this chapter, we will focus on the past, current, and future trends in research and development of peptide-based HIV entry inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI